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292a Monday, February 22, 2010under physiological conditions where receptor function is maintained, we con-
clude that the azido group serves as a more satisfactory chemical handle than
the keto moiety. The fully-functional fluorescently-labeled receptor should
prove useful for kinetic studies of ligand-receptor interaction.
1524-Pos
Probing the Binding Sites and Transmembrane Prolines of GPCRs Using
Unnatural Amino Acids
Ethan B. Van Arnam, Kristina N. McCleary, Michael M. Torrice,
Kiowa S. Bower, Elizabeth H. Jensen, Henry A. Lester, Dennis A. Dougherty.
California Institute of Technology, Pasadena, CA, USA.
We describe a general application of the nonsense suppression methodology
for unnatural amino acid incorporation in functional G protein-coupled recep-
tors (GPCRs). We have evaluated key aromatic residues in the binding sites
of the M2 muscarinic acetylcholine receptor and the D2 and D4 dopamine
receptors. In addition, highly conserved transmembrane proline residues of
the D2 dopamine receptor have been probed with proline analogues and a-hy-
droxy acids. Receptors were expressed in Xenopus oocytes, and activation of
a G protein-coupled, inward-rectifying Kþ channel (GIRK) provided, after
optimization of conditions, a quantitative readout of receptor function. Incorpo-
ration of a series of fluorinated tryptophan derivatives at W6.48 of the D2
receptor establishes a cation-p interaction between the agonist dopamine and
W6.48, suggesting a reorientation of W6.48 on agonist binding, consistent
with proposed ‘‘rotamer switch’’ models. Interestingly, no comparable cat-
ion-p interaction was found at the aligning residue in the M2 receptor. Incor-
poration of a-hydroxy acids at transmembrane proline sites 4.59, 5.50, 6.50,
and 7.50 yielded D2 receptors with EC50 values similar to wild-type, whereas
natural amino acids other than proline proved detrimental to receptor function.
We propose that lack of hydrogen bond donor ability, common to both proline
and a-hydroxy acids, is key to the functional role of proline within GPCR trans-
membrane helices.
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Functional and structural studies on GPCR are ideally conducted on single,
protein-carrying bilayers with unrestricted access for ligands and G-proteins.
It is desirable to have a large accessible surface area and protection from
a solid support. Reconstitution of GPCR into bilayers supported by porous an-
odic aluminum oxide (AAO) nanopores meets those requirements. Extrusion
of proteoliposomes through the nanopores resulted in formation of tubules
of a single lipid bilayer that covers the inner surface of pores. We successfully
reconstituted the GPCRs rhodopsin and recombinant peripheral cannabinoid
receptor CB2 at functional conditions and high concentration into the cylindri-
cal AAO nanopores with a diameter of 200 nm and a length of 60 mm. One
square centimeter of AAO filter yielded 500 cm2 of membrane surface. The
lipid tubules are open at both ends such that buffer passes easily through
the pores. Detergents used for protein reconstitution are flushed out within
minutes. By 2H NMR we demonstrated that neither lipid headgroups nor hy-
drocarbon chains of fluid bilayers are perturbed by the solid support. Photoac-
tivation of rhodopsin in the pores, monitored by UV-vis spectrophotometry,
was indistinguishable from rhodopsin in unsupported liposomes. Metarhodop-
sin-II in the tubules activated G-protein that was delivered through the pore
openings. By NMR diffusion experiments we determined that tubular bilayers
are assembled as short pieces with a length of a micrometer or less that adhere
to the surface by their edges. The tubules possess undulation with a radius of
curvature of 100-400 nm. We have evidence for a layer of water with an
average thickness of 3 nm between the bilayers and the pore surface. It ex-
plains why neither protein function nor fluid bilayer properties are perturbed
by the solid support.1526-Pos
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C-C chemokine receptor 5 (CCR5) is a G protein-coupled receptor (GPCR)
involved in immune responses and it is the primary co-receptor required for
HIV-1 cellular entry. To obtain functional heterologous over-expression of
engineered GPCRs is one of the major hurdles in GPCR research aimed at elu-
cidating structure-activity relationships. It can be especially difficult to obtain
structural information about GPCRs in signaling complexes with other cellular
proteins that form a so-called ‘‘signalosome.’’ We have developed two new
technologies for investigating the structure and function of GPCRs, which
we have now applied to CCR5. First, we have established a membrane nano-
particle system called NABBs (nanoscale apolipoprotein bound bilayers),
which are self-assembling discs that maintain receptors in a native-like mem-
brane environment outside of the cell. We have incorporated functional
CCR5 into NABBs and plan to use this platform to reconstitute the ternary
complex with chemokine ligand and G protein from purified components. In
addition, we have adapted unnatural amino acid mutagenesis for use with
GPCRs. This is a method to incorporate amino acids with unique side chains
at specific sites in the receptor. We introduced p-benzoyl-L-phenylalanine,
into CCR5 at various positions on both the extracellular and intracellular
surface of the protein using the amber suppression technology. Since the ben-
zoyl moiety is a photo-activatable crosslinker, these mutants can now be used
to map the specific sites of interaction between ligand, receptor, and G pro-
tein as predicted from molecular modeling and molecular dynamics simula-
tions. Our methods will form the basis of a new experimental paradigm in
the structural biology of signaling complexes on a mesoscopic level. Ulti-
mately, these methods will be useful for developing a chemically-precise
model for how an extracellular ligand stimulates a GPCR to activate a cyto-
solic G protein.
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Molecularly targeted therapies are at the forefront of clinical science, and are
expected to lead to personalization of medical treatments for each patient.
Most such therapies are directed at inhibiting specific signal transduction en-
zymes or pathways, thus creating a critical need for assays capable of measur-
ing the activities of these proteins in disease models and in patient samples.
The ability to measure relevant enzyme activity in primary cell samples at
baseline and/or after treatment would provide the ability to tailor patient ther-
apy based on aberrant signal transduction, validate mechanisms of resistance
in patients, and would offer an invaluable pharmacodynamic tool to assess
whether resistance is associated with inadequate target inhibition. Here we
report our current efforts to create the analytical and chemical tools needed
to directly measure the enzymatic activities of therapeutic targets including
protein kinases, lipid modifying enzymes and the proteasome. Fluorescent
reagents are under development that report the activity of these various en-
zymes in model cells lines and primary cells. The basic design incorporates
enzyme substrates that are modified to create compounds which can be loaded
into cells where they are modified by the enzyme of interest. Work has in-
cluded modification of peptides to confer membrane permeability and to
achieve long intracellular lifetimes. Microelectrophoretic separations com-
bined with low-level fluorescence detection enable the quantitative analysis
of these compounds from single mammalian cells. This capability addresses
three major issues currently faced in the biochemical analysis of clinical sam-
ples: the need for direct measurement of the enzymatic activity of target
proteins; sample size requirements that are feasible for clinical implementa-
tion; and sample heterogeneity that can mask pertinent aspects related to ther-
apeutic response.
